Triphala

Triphala, an Ayurvedic polyherbal formulation comprising of equiproportional fruit parts of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica[1]. Triphala inhibits NF-κB activation. Triphala exerts antifungal action[2]. Anti-adipogenic, anti-inflammatory, and anti-neoplastic activities.

Signaling Pathways >> Anti-infection >> Fungal

Research Areas >> Cancer

Research Areas >> Inflammation/Immunology

Research Areas >> Infection

NF-κB

Antifungal

Triphala regulates adipogenesis through modulation of expression of adipogenic genes in 3T3-L1 cell line. Triphala significantly decreases the adipogenesis in 3T3-L1 cells by reducing lipid accumulation and inhibiting the expression of adipogenic genes. The 3T3-L1 cells treated with Triphala show ~1.43-, 1.67-, and 2.5-fold decreases in lipid content at 1, 10, and 100 μg/mL concentrations, respectively, compared to the cells treated with induction cocktail alone. Triphala regulates lipid accumulation by down regulating expression of adipogenic genes, resulting into prevention of adipogenesis[1]. Triphala reduces expression of inflammatory mediators such as IL-17, COX-2, and RANKL through inhibition of NF-κB activation[2]. Triphala exerts antifungal action against Asperigillus species and has been reported to inhibit the fungus by up to 37.96% in vitro[2].

[1]. Banjare J, et al. Triphala, Regulates Adipogenesis through Modulation of Expression of Adipogenic Genes in 3T3-L1 Cell Line. Pharmacogn Mag. 2018 Jan;13(Suppl 4):S834-S839.

[2]. Peterson CT, et al. Therapeutic Uses of Triphala in Ayurvedic Medicine. J Altern Complement Med. 2017 Aug;23(8):607-614.

Cycloheximide | BAY 11-7082 | Hygromycin B | Ammonium 1-pyrrolidinedithiocarbamate | SN50 | Triptolide | JSH-23 | Shikonine | Bay 11-7085 | Rocaglamide | (-)-DHMEQ | Dihydroartemisinin | Tomatidine | QNZ (EVP4593) | Cancidas